Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines (2022)

Peer-Reviewed Study · de Baat EC, Mulder RL, Armenian S, et al. (Cochrane Database Syst Rev 2022;9(9):CD014638) · September 27, 2022

de Baat EC et al., 2022-09-27: Cochrane review of dexrazoxane as a cardioprotectant during anthracycline chemotherapy. It found efficacy in adults, a single cardiac outcome favouring it in children, no evidence of reduced tumour response or survival, and in children a possible higher risk of second malignant neoplasms.

Our meta-analyses showed the efficacy of dexrazoxane in preventing or reducing cardiotoxicity in adults treated with anthracyclines.

Abstract (AUTHORS' CONCLUSIONS)

de Baat EC et al., 2022-09-27: Cochrane review of dexrazoxane as a cardioprotectant during anthracycline chemotherapy. It found efficacy in adults, a single cardiac outcome favouring it in children, no evidence of reduced tumour response or survival, and in children a possible higher risk of second malignant neoplasms. Funder: external – Dutch Heart Foundation grant CVON2015-21. Conflicts: one author (SA) contributed to an included trial but did not take part in extraction or GRADE; others none known. Drug: dexrazoxane (Cardioxane/Savene; maker not named in the review). Comparator: placebo or no cardioprotectant alongside anthracyclines. Evidence certainty moderate to low in adults, low to very low in children. PMC9512638. Study type: review.